33.78
+2.02%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Harmony Biosciences Holdings
From its filings with the US Securities and Exchange Commission
Harmony Biosciences Holdings is based in Plymouth Meeting, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HRMY. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $868.5m and net income of $158.7m. At that date it held total assets of $1.27bn and shareholders' equity of $870.2m.
We are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases. To date, we have focused on rare neurological diseases with a growing portfolio now spanning sleep/wake, rare epilepsy, and neurobehavioral and we are harnessing scientific insights and pioneering approaches to advance meaningful treatments that help patients thrive.
In July 2017, we entered into a License Agreement (as amended, the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby we acquired the exclusive right to commercialize the pharmaceutical compound pitolisant. Our lead product, WAKIX® (pitolisant) (“WAKIX”), is a first-in-class therapy with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Since its initial FDA approval in 2019 for excessive daytime sleepiness (“EDS”) in adult patients with narcolepsy and subsequent approvals for cataplexy in adult patients in 2020, EDS in pediatric patients six years and older in 2024 and cataplexy in pediatric patients six years and older in 2026, WAKIX has continued to reshape the treatment landscape for narcolepsy and remains the only FDA-approved treatment for narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (“DEA”).
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Aug 2020
- Employees
- 293
- Head office
- 630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Jeffrey AroninNon-Executive Chairman of the Board, since 2017$40,000
- Dr. Jeffrey DaynoPresident, Chief Executive Officer, Director, since 2017$7.1m
- Mr. Sandip KapadiaChief Financial Officer, Chief Administrative Officer$3.1m
- Dr. Kumar BudurExecutive Vice President and Chief Medical and Scientific Officer$5.7m
- Mr. Adam ZaeskeExecutive Vice President, Chief Commercial Officer
- Mr. Andrew SerafinChief Strategy Officer$2.1m
- Mr. Peter AnastasiouIndependent Director$178,010
- Mr. Antonio GraciasIndependent Director$235,005
- Mr. R. Mark GrafIndependent Director$180,010
- Mr. Ron PhilipIndependent Director
- Mr. Juan SabaterIndependent Director$180,010
- Mr. Gary SenderIndependent Director$302,993
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 4
- Social
- 39
- Governance
- 32
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Harmony Biosciences Holdings Inc has a strong portfolio of patented products that target neurological disorders.
- The company has a highly experienced and skilled management team with proven track records in the pharmaceutical industry.
- Harmony Biosciences has established strong relationships with healthcare professionals and key opinion leaders, enabling effective marketing and distribution strategies.
- The company has a robust research and development pipeline, continuously innovating and developing new treatments for unmet medical needs.
Weaknesses
- Harmony Biosciences operates in a highly competitive industry, with potential challenges from other established pharmaceutical companies.
- The company's heavy reliance on a few key products for revenue generation exposes it to potential risks associated with product failures or market changes.
- Harmony Biosciences' limited global presence may restrict its ability to expand into new markets and reach a wider patient population.
Opportunities
- The increasing prevalence of neurological disorders worldwide presents a significant opportunity for Harmony Biosciences to grow its market share.
- With advancements in technology and healthcare infrastructure, the company can explore partnerships and collaborations to expand its product offerings and reach more patients.
- The growing demand for personalized medicine provides an opportunity for Harmony Biosciences to develop tailored treatments and improve patient outcomes.
Threats
- The pharmaceutical industry faces stringent regulatory requirements and challenges related to clinical trials, which can delay product approvals and market entry.
- Competition from generic drug manufacturers and the potential expiration of patents pose threats to the company's market share and profitability.
- Changes in healthcare policies and reimbursement schemes may impact the pricing and affordability of Harmony Biosciences' products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.